Immune checkpoint inhibitors have radically changed the landscape of antitumor therapies in several malignancies. Despite the long-term efficacy. severe immune-related adverse events (irAEs) were not uncommon. However. https://www.spencertifieders.shop/product-category/cd-cabinet/